ImmuPharma (LON:IMM) Trading 27% Higher – Time to Buy?

ImmuPharma plc (LON:IMMGet Free Report)’s share price shot up 27% during trading on Friday . The stock traded as high as GBX 3.60 ($0.04) and last traded at GBX 3.60 ($0.04). 5,919,609 shares were traded during mid-day trading, a decline of 69% from the average session volume of 18,940,990 shares. The stock had previously closed at GBX 2.84 ($0.04).

ImmuPharma Stock Up 9.3 %

The firm has a 50 day moving average of GBX 1.75 and a 200 day moving average of GBX 1.73. The firm has a market cap of £16.39 million, a price-to-earnings ratio of -393.60 and a beta of 1.53.

About ImmuPharma

(Get Free Report)

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzorâ„¢), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Recommended Stories

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.